FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BRISBANE, Calif., Oct. 31, 2016 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will present how innovative pricing approaches, such as the company’s Responsible Pricing Model, can fortify existing incentives to bring therapies to the U.S. for neglected diseases during the Priority Review Voucher (PRV) Summit in Arlington, Va., November 2-3, 2016.
Dr. Durrant will also participate in a separate panel to discuss PRVs as a model to support the research and development of important medicines.
“The current PRV system is enlightened policy driving both immediate help, and future advancements, for neglected disease patients,” said Dr. Durrant. “We look forward to engaging in the conversation around serving the public health through these effective FDA incentives and responsible drug pricing.”
Details of the presentation and panel follow:
Title: Tackling Neglected Diseases through Responsible Pricing
Date: Wednesday, November 2, 2016
Time: 3:00 – 3:45 p.m. EDT
Presenter: Dr. Cameron Durrant, KaloBios Pharmaceuticals
Title: Panel: Priority Review Vouchers: A New Paradigm for Funding Research
Date: Wednesday, November 2, 2016
Time: 4:15 – 5:15 p.m. EDT
Participants: Xi Chen, PhD, Adena Partners Management; Dr. Cameron Durrant, KaloBios Pharmaceuticals; Charles Keller, MD, Children’s Cancer Therapy Development Institute; Curt H. LaBelle, MD, Global Health Investment Fund
For more information on the conference, please visit http://exlevents.com/priorityreviewvoucher/.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT: Investors: Kim Sutton Golodetz O: 212-838-3777 [email protected] Bruce Voss O: 310-691-7100 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
